Phase II
Selecta Biosciences announced that as part of restructuring efforts it is cutting its current workforce by 36 percent. The company believes that the cuts, along with a reprioritization of its pipeline, will decrease its yearly cash burn by 19 percent.
Viela Bio, based in Gaithersburg, Md., announced that N-MOmentum, its Phase IIb pivotal trial of inebilizumab, met both primary and key secondary endpoints in neuromyelitis optica spectrum disorder (NMOSD).
New biotech Tiburio has surged onto the scene with $31 million in financing and two novel Phase II-ready assets licensed from Ipsen Pharma. The new company, spun out of orphan drug accelerator Cydan is focused on rare endocrine diseases.
Bio-Path Holdings, Inc. provides an update from several clinical development programs and a 2019 business overview
The battle of the bulge is ongoing and it appears that Americans are losing, according to a report from the U.S. Centers for Disease Control and Prevention. The report shows that Americans are losing height and gaining girth.
Capricor Therapeutics has placed a voluntary hold on its Phase II clinical trial for a Duchene Muscular Dystrophy treatment on hold after a patient experienced a severe allergic reaction during dosing.
Gossamer Bio, headquartered in San Diego, announced plans for its initial public offering (IPO) just before Christmas.
Xynomic Pharmaceuticals, a pharma company with roots in both the U.S. and China, forged a deal worth up to $800 million to acquire a Phase II ready cancer treatment from Germany-based Boehringer Ingelheim.
Favorable safety and statistically significant efficacy of oral ABX464 demonstrated in a completed randomized, double-blind, placebo-controlled induction trial based on clinical and endoscopic endpoints
Topline-data from first half of treatment period (one year)
PRESS RELEASES